Our Investors

We have recently completed our Series B round, raising over $100m.
For investment-related inquiries, please contact Joseph Farmer, our Chief Operating Officer.

Chart showing the investors in Xilio Therapeutics Chart showing the investors in Xilio Therapeutics

Xilio News

11/13/2020
Xilio Therapeutics XTX101 (CTLA-4) Poster Presentation at SITC

SITC 2020 reimagined downloadable resource

Read more >

11/12/2020
Xilio Therapeutics XTX201 (IL-2) Poster Presentation at SITC

SITC 2020 reimagined downloadable resource

Read more >

11/12/2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC

Dr Rene Russo

Read more >

11/10/2020
Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Xilio Therapeutics

Read more >

11/06/2020
Xilio Therapeutics Appoints Rachel Humphrey, M.D. to Board of Directors

Read more >

07/23/2020
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Read more >

06/17/2020
Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors

Read more >

04/27/2020
Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer

Read more >

03/02/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing

Read more >

06/12/2019
Akrevia Therapeutics Appoints Joseph Farmer as Chief Operating Officer

Read more >

05/22/2019
Akrevia Therapeutics Appoints ReneĢ Russo, PharmD, as Chief Executive Officer

Read more >

05/16/2019
Akrevia Therapeutics Appoints Distinguished Research Leaders to Scientific Advisory Board

Read more >

03/16/2019
Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies

Read more >

09/27/2018
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture

Read more >